Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6295122 | 0.94 | MAPT (0.58) | MAPTSMN1; SMN2HSD17B10ALOX15ALOX12 | |
| SCHEMBL6293914 | 0.88 | MAPT (0.68) | MAPTSMN1; SMN2HSD17B10ALOX15ALOX12 | |
| SCHEMBL6294891 | 0.87 | MAPT (0.61) | MAPTSMN1; SMN2HSD17B10ALOX15ALOX12 | |
| Hydrochloric Acid SCHEMBL8103004 | 0.86 | MAPT (0.49) | MAPTSMN1; SMN2HSD17B10ALOX15ALOX12 | |
| SCHEMBL6294927 | 0.85 | MAPT (0.61) | MAPTSMN1; SMN2HSD17B10ALOX15ALOX12 | |
| SCHEMBL7792020 | 0.85 | MAPT (0.66) | MAPTSMN1; SMN2HSD17B10ALOX15ALOX12 | |
| SCHEMBL6295123 | 0.84 | MAPT (0.60) | MAPTSMN1; SMN2HSD17B10ALOX15ALOX12 | |
| SCHEMBL8113427 | 0.81 | MAPT (0.54) | MAPTSMN1; SMN2HSD17B10ALOX15ALOX12 | |
| SCHEMBL6298346 | 0.81 | MAPT (0.58) | MAPTSMN1; SMN2HSD17B10ALOX15ALOX12 | |
| SCHEMBL6294922 | 0.80 | L3MBTL3 (0.47) | KMT2AKDM4EL3MBTL1NPC1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6841560-B2 | Substituted isoquinoline derivatives and their use as anticonvulsants | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-01-11 | — | — | US | claimed |
| CN-1183116-C | Substituted isoquinoline derivatives, pharmaceutical composition containing same, preparation method and application thereof | ʷ��˿�������ȳ�ķ����˾ | 2005-01-05 | — | — | CN | claimed |
| US-20030144320-A1 | For treatment and/or prevention of anxiety, mania, depression, panic disorders, nerve sustem disorders | SMITHKLINE BEECHAM P.L.C. | 2003-07-31 | — | — | US | claimed |
| US-20010016657-A1 | Substituted isoquinoline derivatives and their use as anticonvulsants | SMITHKLINE BEECHAM P.L.C. | 2001-08-23 | — | — | US | claimed |
| US-6841560-B2 | Substituted isoquinoline derivatives and their use as anticonvulsants | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-01-11 | — | — | US | disclosed |
| CN-1183116-C | Substituted isoquinoline derivatives, pharmaceutical composition containing same, preparation method and application thereof | ʷ��˿�������ȳ�ķ����˾ | 2005-01-05 | — | — | CN | disclosed |
| US-20040209912-A1 | Substituted isoquinoline derivatives and their use as anticonvulsants | SMITHKLINE BEECHAM P.L.C. | 2004-10-21 | — | — | US | disclosed |
| US-20030144320-A1 | For treatment and/or prevention of anxiety, mania, depression, panic disorders, nerve sustem disorders | SMITHKLINE BEECHAM P.L.C. | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209912-A1 | Substituted isoquinoline derivatives and their use as anticonvulsants | INA, GRIN2C, GRIN2A | MAPT 353/4885SMN1; SMN2 1323/4885HSD17B10 1492/4885 |
| US-20010016657-A1 | Substituted isoquinoline derivatives and their use as anticonvulsants | INA, GRIN2C, GRIN2A | MAPT 353/4885SMN1; SMN2 1323/4885HSD17B10 1492/4885 |
| US-20030144320-A1 | For treatment and/or prevention of anxiety, mania, depression, panic disorders, nerve sustem disorders | PNMT, SLC6A2, GABBR1 | MAPT 1087/4885SMN1; SMN2 1550/4885HSD17B10 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.